Venrock Adviser, LLC
Venrock Adviser, LLC reported 34 holdings worth US$2.06B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Venrock Adviser, LLC reported 34 holdings worth US$2.06B as of Sep 30, 2026. Largest: Oruka Therapeutics, Inc., Erasca, Inc. and Spyre Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 34
- Value as reported
- US$2.06B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Oruka Therapeutics, Inc. | 4.15M | US$346M | 16.8% |
| Erasca, Inc. | 20.1M | US$295M | 14.3% |
| Spyre Therapeutics, Inc. | 2.49M | US$221M | 10.8% |
| Savara, Inc. | 19.6M | US$101M | 4.9% |
| Ocular Therapeutix, Inc. | 10.3M | US$79.4M | 3.9% |
| Dianthus Therapeutics, Inc. | 822K | US$72.4M | 3.5% |
| Viridian Therapeutics, Inc. | 3.26M | US$67.1M | 3.3% |
| Vor Biopharma Inc. | 3.04M | US$58M | 2.8% |
| Cogent Biosciences, Inc. | 1.64M | US$52.6M | 2.6% |
| Adlai Nortye Group Ltd. | 3.21M | US$51.4M | 2.5% |
| Jade Biosciences, Inc. | 3.22M | US$45.2M | 2.2% |
| Achieve Life Sciences, Inc. | 5.5M | US$44.5M | 2.2% |
| Maze Therapeutics, Inc. | 1.55M | US$42M | 2.0% |
| ORIC Pharmaceuticals, Inc. | 2.94M | US$39.7M | 1.9% |
| Dyne Therapeutics, Inc. | 2.17M | US$35M | 1.7% |
| ADARx Pharmaceuticals, Inc. | 1.63M | US$32.4M | 1.6% |
| Crescent Biopharma, Inc. | 2.13M | US$31.1M | 1.5% |
| Relmada Therapeutics, Inc. | 7.45M | US$28.1M | 1.4% |
| Zura Bio Limited | 6.43M | US$26.8M | 1.3% |
| X4 Pharmaceuticals, Inc. | 7.64M | US$22.2M | 1.1% |
| Cullinan Therapeutics, Inc. | 1.38M | US$21.2M | 1.0% |
| Surrozen, Inc. | 633K | US$20.4M | 0.99% |
| Parabilis Medicines, Inc. | 625K | US$20.2M | 0.98% |
| Arvinas, Inc. | 1.95M | US$15.1M | 0.73% |
| Century Therapeutics, Inc. | 8.7M | US$14.9M | 0.72% |
| Artiva Biotherapeutics, Inc. | 2.04M | US$14.6M | 0.71% |
| Alto Neuroscience, Inc. | 500K | US$12.8M | 0.62% |
| Korro Bio, Inc. | 443K | US$4.39M | 0.21% |
| TCGX Acquisition Corp. | 300K | US$3.75M | 0.18% |
| Research Alliance Corporation IV | 300K | US$3.6M | 0.17% |
| InMed Pharmaceuticals Inc. | 133K | US$181K | <0.01% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Cybin, Inc. | 0 | US$0 | 0.00% |
| CytomX Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Damora Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Enliven Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Research Alliance Corporation III | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related